SCHEDULE: Lilly Endowment Maintains Significant Eli Lilly Stake

Lilly Endowment, Inc. reported a 10.1% beneficial ownership stake in Eli Lilly and Company as of September 30, 2025, holding 95,492,993 shares.

Summary

• Lilly Endowment, Inc. filed an Amendment No. 43 to Schedule 13G regarding its beneficial ownership of Eli Lilly and Company common stock.
• As of September 30, 2025, Lilly Endowment, Inc. beneficially owned 95,492,993 shares of Eli Lilly and Company.
• This ownership represents 10.1% of Eli Lilly and Company's common stock outstanding.
• The percentage is calculated based on 946,456,759 shares of common stock outstanding as of August 4, 2025.
• Lilly Endowment, Inc. holds sole voting power and sole dispositive power over all 95,492,993 shares.
• Lilly Endowment, Inc. is a not-for-profit corporation organized under Indiana law, classified as a 501(c)(3) organization and a private foundation.

Sentiment

Score: 7

Explanation: The filing indicates a stable, significant, and long-term institutional ownership, which is generally a positive signal for the company's stability and investor confidence. It's a routine disclosure, so the sentiment is moderately positive due to the implied long-term commitment.

Positives

• Lilly Endowment, Inc. maintains a substantial long-term investment in Eli Lilly, indicating continued confidence in the company's prospects.
• The significant stake held by a private foundation suggests a stable, long-term shareholder base, which can contribute to corporate stability.

Future Outlook

N/A

Industry Context

This filing reflects a significant, long-standing institutional stake in a major pharmaceutical company. Large, stable ownership by entities like endowments can provide a degree of stability to a company's stock, contrasting with more transient institutional investors. This type of ownership often signals a long-term commitment to the company's mission and performance.

Comparison to Industry Standards

• A 10.1% stake is a substantial holding for any institutional investor in a large-cap company like Eli Lilly, indicating a high conviction investment.
• Compared to other major pharmaceutical companies, it is common for large endowments or foundations to hold significant, long-term positions, often stemming from historical ties or philanthropic missions. For example, the Bill & Melinda Gates Foundation Trust holds substantial stakes in various healthcare and pharmaceutical companies, reflecting similar long-term investment strategies.

Stakeholder Impact

• Shareholders: The continued significant stake by Lilly Endowment, Inc. may be viewed positively, signaling long-term confidence and stability in the company's stock.
• Management: A large, stable shareholder like Lilly Endowment, Inc. can provide a degree of oversight and long-term perspective, potentially influencing strategic decisions towards sustained growth.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by Lilly Endowment, Inc. and does not contain new information that would fundamentally alter the investment thesis for Eli Lilly and Company. The continued significant stake by a long-term institutional investor like Lilly Endowment, Inc. reinforces a stable shareholder base, which is generally a positive indicator. However, it does not provide new catalysts for a 'buy' or 'sell' recommendation. Investors should continue to hold based on their existing analysis of Eli Lilly's operational and financial performance.

Keywords

Eli Lilly, Lilly Endowment, Schedule 13G, Beneficial Ownership, Institutional Investor, Pharmaceuticals, Lilly, Equity Stake, Shareholding